Medical aesthetics industry leaders have confirmed that facial fat loss caused by GLP-1 weight loss medications—particularly semaglutide (Novo Nordisk)—is a documented side effect driving increased demand for volume restoration treatments. The phenomenon, colloquially termed "semaglutide face," represents a new and growing patient segment seeking injectable and biostimulator solutions.
Patients on GLP-1 therapy experience rapid weight loss, including loss of facial fat pads and subcutaneous volume. This creates demand for hyaluronic acid fillers, biostimulators (PLLA, CaHA), and combination treatments to restore facial contour and prevent a gaunt appearance. Practices report that GLP-1 patients are often motivated, high-income, and willing to pursue multiple treatment sessions—a favorable demographic for recurring revenue.